FDA Enforcement Class I Ongoing

RITZ PRINCESS, BIOCELL, INTRASHIEL, BioDIMENSIONAL Breast Implant, Styles RML, RMM, RFL, RFM Product Usage: Breast augmentation and Breast reconstruction

Recall: Z-2464-2019 · Reported September 18, 2019

Enforcement

Recall Number
Z-2464-2019
Event ID
83500
Classification
Class I
Status
Ongoing
Product Type
Devices
Firm
Allergan PLC
Voluntary / Mandated
Voluntary: Firm initiated
Initial Notification
Press Release
Report Date
September 18, 2019
Initiation Date
July 24, 2019
Classification Date
September 11, 2019
Address
2525 Dupont Dr, Irvine, CA, 92612-1531, United States

Description

RITZ PRINCESS, BIOCELL, INTRASHIEL, BioDIMENSIONAL Breast Implant, Styles RML, RMM, RFL, RFM Product Usage: Breast augmentation and Breast reconstruction

Reason

The action was initiated following notification by the U.S. FDA of their recently updated, global safety information concerning the higher incidence of anaplastic large cell lymphoma (BIA-ALCL) in patients who have textured breast implants.

Code Info

All Lots: Note:This product was not distributed within the US

Distribution

Worldwide Distribution and US Nationwide All fifty (50) US States, the US Virgin Islands and Puerto Rico. (AK, AL, AR, AZ, CA, CO, CT, DC, DE, FL, GA, HI, IA, ID, IL, IN, KS, KY, LA, MA, MD, ME, MI, MN, MO, MS, MT, NC, ND, NE, NH, NJ, NM, NV, NY, OH, OK, OR, PA, RI, SC, SD, TN, TX, UT, VA, WA, WI, WV, WY). OUS: Bermuda, Canada, Chile, Japan, Korea, Thailand, Taiwan and Vietnam.

Quantity

4,026,287 Breast Implants and Tissue Expanders Combined in total